<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25995" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nosocomial Pneumonia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shebl</surname>
            <given-names>Eman</given-names>
          </name>
          <aff>Zagazig University Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gulick</surname>
            <given-names>Peter G.</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eman Shebl declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Gulick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25995.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nosocomial pneumonia or hospital-acquired pneumonia (HAP) is defined as pneumonia that occurs 48 hours or more after hospital admission and is not present at the admission time. Ventilator-associated pneumonia (VAP) represents a significant subset of HAP occurring in intensive care units (ICUs). This activity reviews the cause, pathophysiology, and presentation of nosocomial pneumonia and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of nosocomial pneumonia.</p></list-item><list-item><p>Review the evaluation of a patient with nosocomial pneumonia.</p></list-item><list-item><p>Outline the treatment and management options available for nosocomial pneumonia.</p></list-item><list-item><p>Describe some interprofessional team strategies for improving care and outcomes in patients with nosocomial pneumonia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25995&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25995">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25995.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nosocomial pneumonia&#x000a0;or&#x000a0;hospital-acquired pneumonia (HAP)&#x000a0;is defined as pneumonia that occurs 48 hours or more after hospital admission and is not present at the admission time. Ventilator-associated pneumonia (VAP) represents a significant sub-set of HAP occurring in intensive care units (ICUs) and is&#x000a0;defined as pneumonia that occurs more than 48 to 72 hours after tracheal intubation and is thought to affect 10% to 20% of patients receiving mechanical ventilation for more than 48 hours.<xref ref-type="bibr" rid="article-25995.r1">[1]</xref><xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
      </sec>
      <sec id="article-25995.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Common pathogens of HAP and VAP include aerobic gram-negative bacilli (e.g.<italic toggle="yes"> Pseudomonas aeruginosa</italic>,&#x000a0;<italic toggle="yes">Escherichia coli</italic>,&#x000a0;<italic toggle="yes">Klebsiella pneumoniae</italic>,&#x000a0;<italic toggle="yes">Enterobacter&#x000a0;</italic>spp,&#x000a0;<italic toggle="yes"> Acinetobacter&#x000a0;</italic>spp) and gram-positive cocci (e.g.,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>, which includes methicillin-resistant&#x000a0;S. aureus,&#x000a0;<italic toggle="yes">Streptococcus&#x000a0;</italic>spp). Differences in host factors and in the hospital flora of an&#x000a0;institution affect the patterns of the causative pathogens.<xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
        <p>
<bold>Risk Factors for Multidrug-Resistant (MDR) VAP</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Septic shock at the time of VAP</p>
          </list-item>
          <list-item>
            <p>ARDS before VAP onset</p>
          </list-item>
          <list-item>
            <p>Intravenous antibiotic use within 90 days of VAP</p>
          </list-item>
          <list-item>
            <p>Hospitalization more than 5 days before the occurrence of VAP</p>
          </list-item>
          <list-item>
            <p>Acute renal replacement therapy before VAP onset&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Risk Factors for MDR HAP&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous antibiotic use within 90 days of HAP&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Risk Factors for MRSA VAP/HAP&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous antibiotic use within 90 days of HAP or VAP&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Risk Factors for MDR Pseudomonas VAP/HAP</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous antibiotic use within 90 days of HAP or VAP.<xref ref-type="bibr" rid="article-25995.r1">[1]</xref><xref ref-type="bibr" rid="article-25995.r3">[3]</xref><xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25995.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>HAP occurs at a rate of 5 to 10 per 1000 hospital admissions and is considered the most common cause of hospital-acquired infection in Europe and the United States. Over 90% of pneumonia episodes developing in ICUs occur in patients who are intubated and mechanically ventilated.<xref ref-type="bibr" rid="article-25995.r1">[1]</xref><xref ref-type="bibr" rid="article-25995.r3">[3]</xref></p>
      </sec>
      <sec id="article-25995.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms may include cough, expectoration, a&#x000a0;rise in body temperature, chest pain, or dyspnea. Signs include fever, tachypnea, consolidations, or crackles.</p>
      </sec>
      <sec id="article-25995.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Clinical Evaluation</bold>
</p>
        <p>Establishing the diagnosis of HAP remains controversial, and there is no superior method. In the guidelines for the management of HAP and VAP by the Infectious Diseases Society of&#x000a0;America/American&#x000a0;Thoracic Society 2016, diagnosis is based upon the presence of a new lung infiltrate and clinical evidence that the infiltrate is of an infectious cause (new onset of fever, purulent sputum, leukocytosis, and a decline in oxygenation). Clinical pulmonary infection score (CPIS), which includes clinical and radiological criteria, is suggested to increase the likelihood of the presence of pneumonia, but some investigators suggest that the CPIS, while being sensitive, lacks specificity and leads to unnecessary antimicrobial treatment<bold>&#x000a0;<xref ref-type="bibr" rid="article-25995.r4">[4]</xref><xref ref-type="bibr" rid="article-25995.r5">[5]</xref></bold></p>
        <p>
<bold>Bacteriologic Evaluation</bold>
</p>
        <p>For patients with VAP sampling the lower airways to get quantitative cultures can be done by:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Blind tracheobronchial aspiration (TBAS)</italic>&#x000a0;is a noninvasive technique done&#x000a0;by inserting a flexible catheter into the distal trachea via the endotracheal tube.&#x000a0;This technique is relatively noninvasive. However, this blind technique prevents direct sampling of the lung segments which have an infiltrate on the radiograph, and this may lead to increasing the false-negative rate. Also, contamination of the suction catheter, as it traverses the endotracheal tube and more proximal airways, may increase the false-positive rate.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Bronchoscopy with bronchoalveolar lavage (BAL)</italic> allows the sampling of the lung segments which&#x000a0;are&#x000a0;suspected to be affected by pneumonia, decreasing the false-negative rate. But, the technique is operator dependent, and contamination of the bronchoscope can affect the results. Also, bronchoscopy can worsen hypoxemia which may not be tolerated by some patients.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Protected specimen brush (PSB)</italic>&#x000a0;can be advanced through a bronchoscope and has the advantage of avoiding contamination with upper airway secretions, as it is not advanced until positioned in the distal airway.<xref ref-type="bibr" rid="article-25995.r6">[6]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>For patients with HAP (non-VAP), noninvasive methods for sampling the lower airways include spontaneous expectoration, sputum induction, and nasotracheal suctioning in a patient who cannot cooperate to produce a sputum sample.</p>
        <p>All respiratory tract samples should be sent for microscopic analysis and culture.</p>
        <p>
<italic toggle="yes">
<bold>Microscopic Analysis</bold>
</italic>
</p>
        <p>The microscopic analysis&#x000a0;includes the analysis of polymorphonuclear leukocytes and a gram stain. Microscopy can be helpful in determining a possible&#x000a0;pathogen and antibiotic selection until the results of the culture are available. The presence of abundant neutrophils and the bacterial morphology may suggest a likely pathogen.</p>
        <p>
<italic toggle="yes">
<bold>Quantitative Cultures</bold>
</italic>
</p>
        <p>Diagnostic thresholds include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Endotracheal aspirates 1,000,000 colony forming units&#x000a0;(CFU)/mL</p>
          </list-item>
          <list-item>
            <p>Bronchoscopic- or mini-BAL 10,000&#x000a0;CFU/mL</p>
          </list-item>
          <list-item>
            <p>PSB 1000&#x000a0;CFU/mL<xref ref-type="bibr" rid="article-25995.r6">[6]</xref><xref ref-type="bibr" rid="article-25995.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>New Molecular Diagnostic Tests</bold>
</italic>
</p>
        <p>New molecular diagnostic tests&#x000a0;like multiplex polymerase chain reaction assay, which detects an array of respiratory bacterial pathogens and many antibiotic resistance genes, offer the advantage of rapid identification of pathogens and resistance patterns for rapid choosing the antibiotic regimens.<xref ref-type="bibr" rid="article-25995.r8">[8]</xref></p>
      </sec>
      <sec id="article-25995.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial empiric therapy for HAP and VAP should include agents active against&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>,&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>, and other gram-negative bacilli. The choice of antibiotics for empiric therapy should be based on the common pathogens and susceptibility patterns within the healthcare facilities and also based on the patient's risk factors for multidrug resistance.<xref ref-type="bibr" rid="article-25995.r9">[9]</xref><xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with HAP who have a risk factor for MRSA infection, specifically those with prior intravenous antibiotic use within 90 days, hospitalization in a unit where greater than 20% of <italic toggle="yes">S. aureus </italic>isolates are methicillin-resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, prescribe an antibiotic active against MRSA like vancomycin or linezolid is recommended (weak recommendation, very&#x000a0;low-quality evidence). Risk factors for mortality include the need for ventilator support due to HAP and septic shock.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>For patients with HAP with no risk factors for MRSA infection and not at high risk of mortality, prescribe an antibiotic with activity against MSSA like piperacillin-tazobactam,&#x000a0;cefepime, levofloxacin, imipenem, or meropenem.</p>
          </list-item>
          <list-item>
            <p>For patients with HAP who have factors for <italic toggle="yes">Pseudomonas</italic> or other gram-negative infection or high risk for mortality, prescribe antibiotics from 2 different classes with activity against <italic toggle="yes">P. aeruginosa</italic> (weak recommendation, very&#x000a0;low-quality evidence). Other patients with HAP may be prescribed a single antibiotic active against <italic toggle="yes">P. aeruginosa,</italic> like piperacillin-tazobactam, cefepime, ceftazidime, levofloxacin, ciprofloxacin, imipenem, meropenem, amikacin, gentamicin, and aztreonam.<xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Continuation Therapy</bold>
</p>
        <p>All patients with HAP or VAP should be reevaluated for clinical response and microbiologic results after initial empiric antimicrobial therapy.</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients in whom the causative organism has been identified, the empiric regimen should be narrowed according to the pathogen's susceptibility.</p>
          </list-item>
          <list-item>
            <p>For patients who are clinically improving and who do not have an identified pathogen, empiric treatment for&#x000a0;<italic toggle="yes">S. aureus or</italic>&#x000a0;multidrug-resistant, gram-negative bacilli can be stopped if these organisms have not been detected in culture from a high-quality specimen within 48 to 72 hours.</p>
          </list-item>
          <list-item>
            <p>Patients who have not improved within 72 hours of starting empiric antibiotics should be evaluated for complications, other sites of infection, and alternate diagnoses. If the diagnosis of pneumonia appears certain, and the patient has risk factors for drug-resistant pathogens, additional pulmonary cultures should be done, and the empiric regimen should be expanded to cover additional resistant organisms.<xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Duration&#x000a0;of antibiotic therapy&#x000a0;in most patients with HAP or VAP of 7 days appears to be as effective as longer durations and may limit the emergence of resistant organisms. However, for patients with a severe illness, bacteremia, slow response to therapy, immunocompromise, and complications such as empyema or lung abscess, a longer duration of therapy&#x000a0;is indicated.<xref ref-type="bibr" rid="article-25995.r2">[2]</xref></p>
      </sec>
      <sec id="article-25995.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acinetobacter</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adenovirus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial sepsis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Burn wound infections&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clostridioides</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Croup</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enterobacter infections&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enterococcal infections&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>E-coli infections</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25995.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Many studies have found that HAP is associated with an increased risk of death. The all-cause mortality associated with VAP ranges from 20 to 50% in different studies. Variables associated with increased mortality include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The severity of illness at the time of diagnosis (eg., shock, coma, respiratory failure, acute respiratory distress syndrome)</p>
          </list-item>
          <list-item>
            <p>Bacteremia</p>
          </list-item>
          <list-item>
            <p>The underlying co-morbidities<xref ref-type="bibr" rid="article-25995.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25995.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) requires an interprofessional team of specialists in infectious diseases, pulmonary diseases, critical care, anesthesiologists, and any clinicians and healthcare providers, including nurses and pharmacists, caring for hospitalized patients with nosocomial pneumonia. Without proper management, the morbidity and mortality from HAP and VAP are high. [Level 2]</p>
      </sec>
      <sec id="article-25995.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25995&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25995">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/nosocomial-pneumonia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25995">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25995/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25995">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25995.s12">
        <title>References</title>
        <ref id="article-25995.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Yassin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhowmick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dixit</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia.</article-title>
            <source>P T</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>767</fpage>
            <page-range>767-772</page-range>
            <pub-id pub-id-type="pmid">29234216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalil</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Klompas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muscedere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El Solh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ewig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fey</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Cruse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>575</fpage>
            <page-range>575-82</page-range>
            <pub-id pub-id-type="pmid">27521441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erb</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bice</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>2258</fpage>
            <page-range>2258-2260</page-range>
            <pub-id pub-id-type="pmid">27925784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagon</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Hospital-acquired pneumonia: diagnostic strategies: lessons from clinical trials.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>717</fpage>
            <page-range>717-26</page-range>
            <pub-id pub-id-type="pmid">15008594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luyt</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chastre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fagon</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia.</article-title>
            <source>Intensive Care Med</source>
            <year>2004</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>844</fpage>
            <page-range>844-52</page-range>
            <pub-id pub-id-type="pmid">15127196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heyland</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heule</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guslits</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jaeschke</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group.</article-title>
            <source>Chest</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>115</volume>
            <issue>4</issue>
            <fpage>1076</fpage>
            <page-range>1076-84</page-range>
            <pub-id pub-id-type="pmid">10208211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baselski</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>el-Torky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coalson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia.</article-title>
            <source>Chest</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>5 Suppl 1</issue>
            <fpage>571S</fpage>
            <page-range>571S-579S</page-range>
            <pub-id pub-id-type="pmid">1424932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burrack-Lange</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Personne</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weile</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knabbe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Multicenter assessment of the rapid Unyvero Blood Culture molecular assay.</article-title>
            <source>J Med Microbiol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>1294</fpage>
            <page-range>1294-1301</page-range>
            <pub-id pub-id-type="pmid">30051799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luyt</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>H&#x000e9;kimian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koulenti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chastre</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>332</fpage>
            <page-range>332-338</page-range>
            <pub-id pub-id-type="pmid">30036192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25995.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karakuzu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Iscimen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akalin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelebek Girgin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kahveci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sinirtas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Risk Factors in Ventilator-Associated Pneumonia.</article-title>
            <source>Med Sci Monit</source>
            <year>2018</year>
            <month>Mar</month>
            <day>05</day>
            <volume>24</volume>
            <fpage>1321</fpage>
            <page-range>1321-1328</page-range>
            <pub-id pub-id-type="pmid">29503436</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
